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ABSTRACT 
Background & Aims: Intrahepatic cholangiocarcinoma (ICC) is the second-most 
lethal primary liver cancer. Little is known about intratumoral heterogeneity (ITH) 
and its impact on ICC progression. We aim to investigate its ITH in hope of helping 
develop new therapeutic strategies.  
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Methods: We obtained 69 spatially distinct regions from 6 operable ICCs. Patient-
derived primary cancer cells (PDPCs) were established for each region, followed by 
whole-exome sequencing(WES) and multi-level validation. 
 
Results: We observed widespread ITH for both somatic mutations and clonal 
architecture, shaped by multiple mechanisms, like clonal “illusion”, parallel evolution 
and chromosome instability. A median of 60.3% mutations were heterogeneous 
mutations, among which 85% of the driver mutations located on the branches of 
tumor phylogenetic trees. Many truncal and clonal driver mutations occurred in 
tumor-suppressor genes, such as TP53, SMARCB1 and PBRM1 that involved in DNA 
repair and chromatin-remodeling. Genome doubling occurred in most cases (5/6) after 
the accumulation of truncal mutations and was shared by all intratumoral subregions. 
In all cases, ongoing chromosomal instability is evident throughout the evolutionary 
trajectory of ICC. The recurrence of ICC1239 provided evidence to support the 
polyclonal metastatic seeding in ICC. The change of mutation landscape and internal 
diversity among subclones during metastasis, such as the loss of chemoresistance 
mediator, may be used for new treatment strategy. Targeted therapy against truncal 
alterations, such as IDH1, JAK1, and KRAS mutations and EGFR amplification, 
could be developed in 5/6 patients. 
 
Conclusions: Integrated investigations of spatial ITH and clonal evolution may 
provide an important molecular foundation for enhanced understanding of 
tumorigenesis and progression in ICC. 
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Lay summary 
We applied multiregional whole exome sequencing to investigate the 
evolution trajectory of ICC. The results revealed that many fuels, such as 
parallel evolution and chromosome instability, may participate and promote 
the branch diversity of ICC. Interestingly, in one patient with primary and 
recurrent metastatic tumors, we found some clues of polyclonal metastatic 
seeding, indicating that symbiotic communities of multiple clones existed and 
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were maintained during metastasis. More realistically, some truncal alterations, 
such as IDH1, JAK1, and KRAS mutations and EGFR amplification, can be 
promising treatment targets for ICC patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Intrahepatic cholangiocarcinoma is the second most frequent type of primary liver 
cancer with an increasing global incidence during the past decades. Although 
hepatectomy is the curative method for early ICC, 5-year survival rate after resection 
wavers around 30-35% [1]. For those in the late stage that only receive cisplatin-
based chemotherapy, the median overall survival is as low as 11.7 months[2]. The 
lack of commonly-accepted effective of medical care highlights the importance of 
understanding the ICC pathogenesis to develop new treatment strategies[3]. 
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Recently, genomic sequencing studies have taken insights into the genetic landscape 
of ICC[4-6]. The driver alterations identified in ICC may represent potential 
candidates for personalized targeted therapy. However, genomic alterations identified 
in most of these studies were obtained by single sampling in individual cases, and 
little is known about the spatial ITH or temporal clonal evolutionary processes in 
ICC. In fact, anti-tumor drug development may require not only an understanding of 
genetic alterations but also an apprehension of the clonal status of driver alterations 
and evolutionary processes. During tumor progression, accumulating somatic 
mutations bestow a selective advantage on subclonal expansion, through which the 
fittest subclone will dominate. In turn, the presence of subclonal mutations may affect 
the efficacy of the targeted therapy. For example, in BRAFV600-mutant melanoma, 
the subclonal heterogeneity of PI3K-PTEN-AKT signaling are involved in the 
resistance to BRAF inhibitors[7]. Therefore, therapeutics targeting clonal somatic 
events or combination of multiple target sites seems to be more effective. 
Studies adopting multiregional WES have unveiled the complex ITH and evolution 
pattern in several types of cancer, including prostate cancer, hepatocellular carcinoma 
and non-small cell lung cancer [8-11]. Since ICC contains a large proportion of non-
tumor components [12], sequencing tumor sample directly may be confounded by low 
tumor purity, resulting in unexpected impacts on the accuracy of mutation landscape 
and clonal structure.  As a countermeasure, PDPCs obtained by single sampling 
were developed for their high purity and cell population representativeness[13]. 
Previous study on hepatocellular carcinoma and lung cancer have shown that PDPCs 
can be an accurate assessment of intratumor genetic heterogeneity and represent a 
potential powerful tool for drug screening[13-15]. 
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To reconstruct the genome history and evaluate how clonal structure can affect 
therapeutic responses in ICC, we performed multiregional WES of 6 ICC tumors 
containing a total of 69 related PDPCs that represented the broad intratumor 
mutational spectrum. The multiregional cell culture model derived from geographical 
sampling allowed us to study mutation frequencies, observe clonal evolution, and 
correlate evolution process with therapy development for ICC. 
 
Method: 
Patients and Sample Collection  
Samples were collected from patients diagnosed with ICC who underwent curative 
resection without any adjuvant therapy before. All 6 patients were from Zhongshan 
Hospital of Fudan University. Patents’ clinicopathologic information was presented in 
Supplementary Table 1. After resection, characteristic spatially separated regions of 
each primary tumor were collected as previously described[15].  Major part of each 
region was subjected to primary culture, and minor part was sent to H&E staining. 
Details of the establishment of PDPCs are described in the Supplementary Material. 
The study was approved by the Research Ethics Committee of Zhongshan Hospital, 
and written informed consent was obtained from each patient.  
 
WES, Sanger validation, Fluorescent in situ hybridization, 
Immunohistochemistry, Cell proliferation assays, Genome-wide analysis of 
mutation calling, copy number alteration (CNA) and phylogenetic tree 
construction, and Statistical analysis. 
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see Supplementary Materials and Methods sections. 
 
RESULTS 
Establishment of multiregional patient-derived primary cancer cells from ICC 
To illustrate ITH in ICC, fresh tissues were collected from 69 spatially distinct tumor 
regions (range, 7–16 per case) in 6 cases, who received curative resection 
(Supplementary Table 1). In particular, ICC1239P and ICC1239R were resected from 
the same patient, the latter of which was a recurrent lesion after 7 months of primary 
resection. Each sample was subjected to low-passage primary culture to generate 
PDPCs, followed by STR typing identification and WES (Graphical abstract). WES 
achieved a mean coverage of 100X on those 69 low-passage PDPCs and matched 
peripheral blood samples, as well as 300X on the corresponding tumor tissues 
(Supplementary Table 2). 
As the low-passage primary culture would filter out most of the non-proliferative 
stromal components, the average purity of PDPCs finally achieved 94.4%(range, 
67%-98% ), compared to 40%(range, 20%-54%) in the tumor tissues(Supplementary 
Figure 1A). Thus, the high purity of PDPCs could minimize the confounding effect of 
non-tumor components on genomic analysis and was more conducive to build a 
model close to the real clonal structure[16]. Moreover, in each patient, the number of 
mutations detected in multiple PDPCs was significantly higher than that in its 
corresponding tissue (median, 832 vs 312) , while the mutations detected in the tissue 
with 300X sequencing depth was higher than those detected in any single PDPC with 
100X depth  (Supplementary Figure 1B), indicating that both multi-regional 
sampling and higher sequencing depth could improve the efficiency of mutation 
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detection. In addition, consistent with previous studies [13,15], there existed a similar 
mutation spectrum and mutation types between PDPCs and corresponding tissues. 
Altogether, multi-regional PDPCs could cover the whole mutation landscape and 
clonal structure more efficiently. 
 
Spatial intratumor heterogeneity and clonal status of SNV 
We identified a total of 1,596 non-silent mutations, including 1,312 missenses, 85 
nonsenses, 25 splice-site variants and 174 insertions or deletions in those 69 PDPCs. 
Sanger validation of 1,331 randomly selected non-silent somatic mutations showed a 
high true discovery rate (94.4%) (Supplementary Table 4). Median number of non-
silent mutations was 93 in each PDPCs and regions from same patients had similar 
numbers of mutations (Figure 1A, Supplementary Figure 2 and Supplementary Table 
3). We found a high degree of spatial ITH in ICC. The median ITH index 
(Supplementary Method) is 60.3% (range 45.6%-71.6%), which is substantially 
higher than other cancers, such as esophageal adenocarcinoma (25%), non-small cell 
lung cancer (30%) and hepatocellular carcinoma (39%) [9,15,17]. In addition, we 
found that the genetic variability increased linearly with the number of sampling 
regions[18], showing that more regions were needed to accurately estimate the ITH 
level (Figure 1B).  
For each individual region, we calculated the cancer cell fraction (CCF) and classified 
the mutations as clonal or subclonal using Pyclone[19]. Notably, almost a half of 
mutations (median 42.8%, range 8.3% to 79.4%) were classified as subclonal,  
implying that each individual region had high level of heterogeneity (Figure 1C, 
Supplementary Figure 3). The proportion of subclonal mutations in the regions was 
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higher than that of the cancers previously reported based on the TCGA data, such as 
bladder cancer (~18%), glioblastoma (~32%) and lung adenocarcinoma (~30%)[20]. 
Remarkably, duo to great variations in some given variant allele frequency among 
regions, a number of variants detected as clonal within some tumor regions were 
subclonal or absent in other regions from the same patients, producing an “illusion” of 
clonal dominance[9,21], and these clonal illusion mutations were detected in nearly 
all regions (Figure 1D). For instance, in ICC892, a missense mutation in KDM3A 
(pAla776Val), a member of the Jumonji C-domain-containing histone demethylases 
involved in cisplatin-resistance in ovarian cancer and tamoxifen-resistance in breast 
cancer[22,23], was estimated to be clonal in regions R2, R3 and R8 but was subclonal 
in all other 8 regions (Figure 1E). In fact, without multiregional WES, nearly 8% of 
subclonal mutations would be misinterpreted as clonal events. This misinterpretation 
may have serious adverse influence on the targeted therapy if only one region was 
used for sequencing analysis. 
 
Tumor evolution of ICC 
We further used Pyclone to construct phylogenetic tree to elucidate the evolutionary 
trajectory of each patient[19] (Figure 2A). On the phylogenetic trees, each cluster 
represented a node and the branch length was proportional to the mutation numbers in 
the corresponding cluster. In each patient, the trunk cluster consisted of clonal 
mutations and occured at early tumor stage. The trunk mutations formed the  
mutational profile of the founder population, representing optimal therapeutic targets. 
All the 6 patients displayed clear evidence of branched evolution. About half of the 
tumor regions (35/69, 50.2%) carried subclones located in only a single branch of the 
phylogenetic tree, once again demonstrating a high level of heterogeneity. The trunk 
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cluster of other cancer types often held the majority of the driver genes [9,17,24]. 
However, the driver genes in ICC were scattered along the phylogenetic tree, with 
only a minority located in the trunk. On average, trunk had only 4.3(15%) driver 
mutations and non-trunk had 24.7(85%) driver mutations. This indicated that the force 
to drive tumor diversity persisted along ICC evolution (Figure 2B). Considering the 
heterogeneity and the complex regulating network in ICC development[4,5,25], we 
clustered non-truncal missense genes into multiple pathways using the KEGG 
database, which exhibited that cAMP signaling, Calcium signal, cGMP-PKG signal, 
Gap junction and ECM-receptor pathways may have a crucial role in ICC progression 
(Figure 2C). We also adapted a dN/dS model to quantify the selection pressure in the 
tree. Although these data were still limited, dN/dS~1 appeared to characterize somatic 
evolution in ICC, while the ratio in missense mutations was higher than that in 
nonsense mutations (Wilcoxon test, p=0.006) (Supplementary Figure 4).  
The same patient could have different and seemingly functional redundant mutations 
in the same driver gene. This is consistent with the parallel evolution that the same 
genetic pathway within a tumor was independently destroyed in different tumor 
subpopulations[26]. For example, in ICC772, two separate subclonal lineages, R3 and 
R7, carried different USP6 driver mutations that may activate USP6 oncogenic 
function and affect the Wnt signaling individually[27] (Figure 2E). Meanwhile, 
previous studies revealed that parallel evolution might also be driven by focal 
amplification[9,28]. In ICC892, the gene SMARCB1, a chromatin remodeler gene, 
had a trunk amplification, but they were further amplified in subclonal clusters and 
finally resulted in copy number hyper-diversity in the tumor sub-regions. These 
amplifications were validated by fluorescent in situ hybridization(FISH) analysis, 
using 2 probes labeling SMARCB1 (green) and 22q12 (red) respectively (Figure 2F). 
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Interestingly, the amplified alleles were always the SMARCB1-mutated 
(p.Arg367Met) allele.  
When chromosome damage persisted, the expression of SMARCB1 might be up-
regulated by multiple mechanisms, such as amplification, transcriptional and post-
transcriptional regulation, while loss-of-function mutation in this gene may have 
interference in actual effect of amplification. Therefore, high expression of 
SMARCB1 mainly reflected the high level of chromosomal instability (CIN) and 
might be related with ICC prognosis. Immunostaining showed a typical nuclear 
staining of SMARCB1 in ICC, and 63% (197/311) of patients displayed up-regulation 
of SMARCB1[25] (Figure 2G). SMARCB1 expression was independent of patients’ 
clinicopathologic characteristics(Supplementary Table 5), and its high expression 
significantly correlated with dismal clinical outcome (Figure 2H). Multivariate 
analysis also confirmed SMARCB1 expression as an independent prognosticator for 
recurrence (hazard ratio [HR], 1.37; 95% confidence interval [CI], 1.01–1.85; P= 
0.043) and survival(HR, 1.59; CI, 1.19-2.97; p=0.002) (Supplementary Tables 6 and 
7).  
 
Temporal dissection of mutational spectrum and signatures 
We further analyzed the mutational spectrum based on the timeline of mutation 
acquisition, i.e., early trunk, late trunk and non-trunk mutations. Among all mutations, 
C>A transversion, C>T and T>C transitions were the predominant changes, a feature 
shared by hepatocellular carcinoma and ICCs[29]. Similar to previous reports in ICC 
[5,6], the C>T transitions in our 6 ICCs were enriched in CpG sites, implying a 
common mechanism underlying ICC pathogenesis. In addition, C>A transversion 
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increased dramatically in non-trunk mutations, while the proportion of T>C transition 
decreased in non-trunk (Figure 3A and 3B).  
To figure out the cause of such mutation shift, we analyzed the mutation signatures 
using DeconstructSigs to map the mutation to the COSMIC signatures[30](Figure 6a). 
The signatures in the trunk and non-trunk mutation demonstrated significant 
differences. Correspondending to the change of C>A transversion, signature 24, 
observed in a subset of hepatocellular carcinoma that correlated with aflatoxin B 
exposure, displayed a prominent increase only in non-trunk events, especially in 
ICC880 and ICC1969. Additionally, the tobacco-related signature 29 was elevated in 
non-trunk events, consistent with the smoking history of these patients. Moreover, 
signature 5 was increased in 4 ICC patients, but the etiology of this signature was still 
unknown. These ICCs could acquire different branched driver genes with similar 
mutation signatures, indicating the innate essence rather than the mutation signatures 
may be the predominant fuel for branch process(Figure 3C). 
The distribution of signatures in the trunk was more diversified than that in the non-
trunk (Figure 3C), implying that complicated etiology may be involved in the 
tumorigenesis of different individuals. Signature 1, reflecting spontaneous 
deamination of methylated cytosines, was identified in ICC880 and ICC1969 and was 
significantly more prevalent in the trunk mutation. This signature was associated with 
ICC patient age at diagnosis, indicating these initial mutations may accumulate with 
age. Another tobacco-related signature, signature 4, was found in the trunk, indicating 
that effect of tobacco consumption will affect the entire evolution process. Signature 
16 was also found to be elevated in the trunk mutation. Signature 16 was linked with 
an exceptionally strong transcriptional strand bias for T>C mutations at ApTpN 
context but its etiology was still unknown. 
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The heterogeneity of CNA and chromosomal instability  
We next analyzed heterogeneity at the copy number level. In contrast to high degree 
of ITH in somatic mutations, CNAs showed less degree of intra-tumor heterogeneity.  
We detected deletions on chromosomes 1p, 4q, 7q, 8p, 13q, 16q and 22q (deletion: 
<=1 copy number relative to ploidy). These deletions harbored well-known tumor 
suppressors, such as TP53 (17p13), RB1 (13q13) and ARID1A (1p36).  ARID1A 
was identified as an ICC driver in previous genomic sequencing studies[5,6], and its 
inactivation was proved to promote ICC carcinogenesis[5]. We also noted high level 
of amplification on chromosomes 6p, 7p, 8q, 9q and 12p, 22q (amplification: >= 2X 
ploidy). Known oncogenes, such as EGFR, CDK6, MET, MYC, HOXA9, and 
SALL4, were located in these regions (Figure 4A). Circos plot of 6 patients were also 
drawn to present the CNA profiles (Supplementary Figure 5). In addition, the somatic 
CNAs in our cohort were compared with those in another 99 ICC patients using an in-
house algorithm based on BICseq2 and GISTIC2.0[6,31,32]. In total, 30 amplified 
segments and 20 loss segments also existed in at least one sample in our cohort, 
indicating a significant overlap with this dataset (Figure 4B). Deletions of both TP53 
and ARID1A were found in half of ICCs (50/99), and high frequent amplification of 
the above oncogenes were also observed. 
Remarkably, except for ICC1239 (diploid), the remaining 5 cases held high-ploidy 
karyotypes. ICC772, ICC 892, ICC1370 and ICC1969 were triploid and ICC 880 was 
tetraploid(Figure 4A). The allele information of these high-ploidy tumors showed  
that genome doubling (GD) was shared by all regions and hence GD would be an 
early event in tumor progression. All the high-ploidy patients held the deletion of 17p, 
where the tumor suppressor gene TP53 located. Increasingly more evidences indicted 
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that GD events were associated with increased CIN and may forecast poor 
prognosis[33]. Previous study showed that a 20% threshold of the weighted Genome 
Instability Index (wGII) could accurately distinguish CIN+ from CIN− tumors[34]. 
We found that all tumor regions in our cohort demonstrated high levels of wGII 
(median, 0.67; range, 0.31–0.93), indicative of CIN+. Considerably higher wGIIs 
were detected in high-ploid (ploidy ≥3) than diploid tumors, consistent with the results 
in colorectal cancer[33](Figure 4C). Alternatively, studies reported that microsatellite 
instability existed in some ICC with a more favorable outcome and could predict the 
response to PD-1blockade [35,36]. However, samples in this cohort showed very low 
MSI scores (Supplementary Figure 6). These data conformed with the model that 
extensive CIN occurred along with the evolution and provided sufficient fuel for 
clonal diversification in ICC.  
 
Timing of Clonal mutations and chromosomal alterations  
Alterations in a number of driver genes were mostly truncal and occurred before GD, 
indicating their involvement in tumor initiation. For instance, other than SMARCB1, 
several other SWI/SNF complex gene, including SS18, PBRM1 and SMARCC1, also 
harbored clonal inactivating mutations in 4/6 cases, and most of them occurred before 
GD. In our 5 high-ploidy ICCs, GD was found to mainly occur later in the trunk, 
resulting in mutated allele copy number ≥2 for most of truncal mutations (median 
83%, range, 78-89%). In other word, a significant mutational burden had already 
accumulated before GD in ICC.  
Clonal chromosomal-arm alterations were further timed by mutated allele copy 
number of all genes on a given arm. In the 5 ICC, early alterations were estimated to 
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include the amplifications of 6p, 7p and 12p and the LOH of 1p, 8p, 13q and 22q12 
before GD. For example, 22q12 LOH (2+0), harboring the tumor suppressor NF2, 
was likely to have occurred prior to GD and promote the initiation of ICC892; 
Otherwise, it would require two independent hits. The copy number of 22q12 was 
validated by FISH analysis in regions R3, R8 and R9(Figure 2F, the red spot).  
 
Intrahepatic metastasis and polyclonal seeding 
Next, we assessed the temporal association between the primary and recurrent lesions 
in ICC1239. Considering that both of them shared the same clonal mutations and 
similar mutation spectrum, we inferred that ICC1239R was formed by the early 
intrahepatic metastasis from the primary tumor ICC1239P, rather than a new multi-
centric tumor(Figure 5A). If a recurrence was seeded by single tumor cell, it should 
carry a series of alterations that presented in all tumor cells. However, in ICC1239R, 
multiple mutational clusters presented subclonally in more than one recurrent region. 
The recurrence would thus most likely come from multiple seeding by two or more 
distinct primary clusters, indicative of polyclonal metastatic seeding in ICC (Figure 
6B and 6C). The multiple seeding events could be attributed to two factors: first, a 
cooperative relationship existed among these clusters; second, early colonization was 
actively involved in remodeling local microenvironment to make it conducive to later 
colonization. Consistently, recent studies revealed subclonal reciprocal interaction 
through Wnt and Notch pathways to promote cancer metastasis[37,38].  
Moreover, ICC1239R had an equal number of clonal mutations but much fewer 
subclonal mutations compared to ICC1230P (Supplementary Figure 4). Many 
subclonal mutations in primary site, such as mutations in the genes KIAA0232 and 
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IGF2BP3, could not be detected in the recurrence. This was consistent with the 
“founder effect” theory that the diversity of genome alteration in the metastases was 
much less than primary tumor[39,40](Figure 5B and 5C). In addition, new oncogenic 
events occurring during metastatic progression would endow the recurrence with a 
new phenotype. Although ICC were highly chemoresistant tumor, genetic alterations 
related to chemoresistance would make ICC1239R respond differently to 
chemotherapy. For example, a nonsilent mutation in PFKP (p.Ile752Leu), a gene that 
potentiated cancer cell survival under metabolic stress and mediated resistance to 
cisplatin in ovarian cancer[41], was clonal in the region ICC1239R_R2, but 
undetectable in all other primary or recurrent regions. Additionally, two 
chemoresistance-related genes in ICC1239R_R2 exhibited copy-number loss. One 
was a nucleotide excision repair gene ERCC2. Its deficiency would contribute to 
cisplatin sensitivity in urothelial cancer and non-small cell lung cancer[42,43]. The 
other was AKT-2. The loss of AKT-2 could lead to apoptosis via Bcl-2 
downregulation and Bax upregulation, and sensitize cells to cisplatin[44]. Therefore, 
we tested the effect of cisplatin on cell viability of the primary cells derived from 
1239R_R1/R2 in vitro, and the result was consistent  with the genomic 
prediction(IC50 of R1 and R2: 11.3μmol/L and 3.5μmol/L respectively)(Figure 5D). 
These alterations thus indeed made ICC1239R_R2 more sensitive to cisplatin-based 
chemotherapy than other regions.  
 
Potential target strategy for ICC treatment 
We next considered all alterations with available or in-development therapeutics. To 
maximize tumor response, the most prior strategy was to target clonal events in all 
tumor cells. In 5/6 patients, there were actionable clonal truncal mutations (see 
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Supplementary Material). TP53 in ICC1370 and ICC880, SMARCB1 and RB1 in 
ICC892 were clonal in all the regions, but there were no FDA-approved drugs 
targeting these genes. ICC1239 had a truncal IDH1 mutation (p.Arg132Cys) and a 
JAK1 mutation (p.Tyr1059Cys). The IDH inhibitor AG-120  and JAK inhibitor 
Ruxolitinib might be used for these two mutations. ICC880 had a truncal KRAS 
mutation (p.Gly12Asp) and the patient may benefit from Panitumumab or 
combinational treatment of Cetuximab plus chemotherapy[45,46]. Except region R3, 
EGFR amplification were detected in all regions of ICC1969,, making them 
potentially sensitive to Gefitinib[47](Supplementary Figure 7). We selected 
Gefitinib, an EGFR inhibitor, to test its effect on cell viability of PDPCs from 
ICC1969 using ICC772 cells without EGFR alterations as a control. The results 
showed that EGFR amplification indeed made ICC1969 cells more susceptible to 
anti-EGFR therapy (Supplementary Figure 8). 
Considering the clonal structure in the recurrence ICC1239R, adaptive therapy, an 
evolution-based therapeutic strategy that aimed to prolong time to progression rather 
than to reduce tumor size[48], would be optimal to control its progression. 
ICC1239_R2 was sensitive to cisplatin-based chemotherapy, and thus would cost 
fewer intracellular resources to maintain resistance and consequently have higher 
fitness than resistant cells when not treated [49](Figure 5E). In this model, the patient 
may be first given targeted trunk therapy, such as Ruxolitinib and AG-120, to dwindle 
the population of all clusters, followed by a non-treatment stage to allow the cell 
population with higher fitness (1239_R2) to expand and suppress the growth of 
chemo-resistant population. Next, a cisplatin-based chemotherapy in low and short 
burst dosage would be applied to kill most of the sensitive cells with little influence 
on resistant population and then be withdrawn. Gradually, the resistant population 
would be inhibited by the sensitive population and grow slowly and another round of 
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targeted trunk therapy could be initiated again when the resistant population did 
progress. Adaptive strategies like adjusting the conduction of the drug vacations and 
treatments targeting different tumor branches, in conjunction with medical imaging or 
liquid biopsy to monitor subclonal growth ratios, could stimulate clonal competition 
and restrain general tumor growth[50].  
 
DISCUSSION 
In this study, we depicted an overall picture of intratumor genetic heterogeneity and 
unmasked the evolutionary trajectories in ICC. Our results demonstrated that multiple 
evolutionary mechanisms, like branch evolution and parallel evolution of late 
mutations, “illusion” of clonal dominance and polyclonal metastatic seeding, had 
important roles in ICC progression. In addition to intrinsic genetic instability, we 
found that extrinsic factors, such as carcinogenic exposure, smoking history, aging 
and others, might collectively contribute to shape intratumor genetic heterogeneity of 
ICC. Notably, all the tumors in our cohort carried subclonal driver alterations, 
stressing the importance of spatial heterogeneity in ICC on fully capturing tumor 
evolutionary history and on more accurately identifying driver events as attractive 
therapeutic targets(Figure 6). 
The evolution trajectory was constructed based on somatic alterations to reflect the 
history of ICC development, showing that branch evolution was the dominant pattern. 
In fact, several targetable driver mutations, including those in JAK1, IDH1, and 
KRAS, were almost exclusively truncal events, which could be optional targets for 
devising new therapies. However, over 85% of putative driver mutations, such as 
ERBB2, CTNNB1, NOTH1, HIF1A, TTN, KDM3A and IKZF1[5,6,51,52], were 
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found to be subclonal in these 6 ICCs. Furthermore, evidence of parallel evolution of 
branch alterations in both SNVs and CNAs was noted, and FISH-based analyses 
confirmed the heterogeneity of copy-number changes. These  driver alterations in 
parallel branches were relatively late events during tumor evolution and represented 
the constraints imposed on cancer development. Therefore targeting parallel 
evolutionary events and exploiting these cancer dependencies may be a compelling 
approach. In a word, we can reasonably infer that the trunk mutations in ICC may just 
confer fundamental ability for tumorigenesis, while the non-truncal mutations 
preferentially favor distinct subclonal expansions after establishment of the founding 
clones. 
Meanwhile, our study also provided information on the divergent chromosomal 
instability processes related to ICC evolution and their dynamics over time. GD 
events, a macro-evolutionary step in cancers[33], were observed in 5 out of 6 ICC 
patients. In all 5 patients, genome-doubling events were found to occur before 
subclonal diversification but after acquisition of most of early driver mutations, 
consistent with findings in colorectal and esophageal cancer that GD may accelerate 
cancer genome evolution[17,33]. Furthermore, we found that all tumor regions in our 
cohort demonstrated high levels of chromosomal instability index, along with 
mutations or deletions in specific genes involved in maintaining genome integrity and 
DNA repair, e.g. the chromatin remodeling complex. It is worth noting that truncal 
mutations can be lost by later copy-number deletion, which will restrict the potential 
of targeted truncal strategy, especially in tumors with high chromosomal instability. 
Consequently, these findings suggested that chromosomal instability was wide-spread 
in ICCs at both early and late stage and fueled for evolution process. As a potential 
therapeutic strategy, reduced genome instability may limit the ensuing heterogeneity 
and adaptability of cancer cells to treatments. 
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Interestingly, in ICC1239 with primary and intrahepatic metastatic tumors, the clear 
evidence of polyclonal metastatic seeding supported that tumors existed as symbiotic 
communities of multiple clones that were maintained during metastasis[53]. Despite 
intratumor heterogeneity, the truncal alterations were generally consistent between the 
primary and intrahepatic metastasis, indicating that multi-region sequencing of 
primary tumor could be adequate to find the targets in the trunk to deal with the 
metastasis. Meanwhile, genetic diversity of polyclonal populations could be greatly 
reduced in the metastasis by the “founder effect”, with several newly-acquirred 
alterations. New alterations in 1239R_R2 made it more sensitive to the cisplatin than 
other recurrences, validated by in vitro drug test, which might provide a theoretical 
basis for adaptive therapy and showed a potential to evoke the competition between 
clonal subgroups in ICC.  
Several limitations may undermine this study. First, although M-WES achieves more 
tumor diversity than single biopsy, the tissue it sampled is still limited. Hence, this 
approach still underestimates the number of subclones present within a given tumor, 
leading to limited resolution of the evolutionary trajectory. Conceivably, higher 
sequencing depth and integrated omics data, like epigenomics, transcriptomics and 
proteomics, may help to generate fine structure. Second, comparing to somatic 
mutations, detection of subclonal CNAs remains challenging, and significant 
subclonal amplifications or deletions may be ignored. Novel technologies, such as the 
third-generation sequencing, are needed to overcome the limitation. Third, therapeutic 
strategies proposed here need further validation in large-scale preclinical and clinical 
studies.  
In summary, integrating PDPCs culture and multiregional WES, we revealed strong 
spatial, temporal ITH and diversity of clonal status, constructed the clonal evolution 
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trajectory in ICC, and marked the chromosomal instability as the main power source 
of evolution. 
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Figure 1:  Intratumor genetic heterogeneity of ICC.  (A) Number of somatic 
SNVs and the distribution of different mutation types.  (B) The relationship between 
detected genetic variability and the number of samples acquired within a tumor.  (C) 
The distribution of CCF 95%CI among all mutations. This plot includes the mutations 
with <5% CCF, which have been excluded for further analysis.  (D) Barplot shows 
all subclonal mutations, and it will be counted as clonal illusion (blue) if one appears 
clonal in at least one region.    (E) Representative probability distributions over the 
CCF of KDM3A in ICC892. 
 
 
Figure 2: Phylogenetic tree and parallel evolution.  (A) Coxcomb plots presenting 
the clinical information and ITH parameters(upper panel) and reconstruction of 
phylogenetic trees in the 6 cases(lower panel).  (B) The distribution of driver genes 
in the trunk and non-trunk.   (C) The main pathways involved in the non-trunk 
alterations, referring to the KEGG database.  (D) Parallel evolution in ICC772 
driven by two different USP6 mutations.  (E) Parallel evolution of amplification of 
SMARCB1 in ICC892. The copy number of SMARCB1 progresses step by step, 
validated by FISH analysis.  (F) Representative immunostaining images of 
SMARCB1 protein in normal liver tissue and ICC. Samples with scores 0 and 1 are 
divided into SMARCB1low group, and scores 2 and 3 into SMARCB1high group. Scale 
bars=100um.  (G). Kaplan-Meier curves showing increased recurrence and dismal 
survival in patients of SMARCB1high group. 
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Figure 3: Temporal dissection of mutational process and signatures in ICCs   
(A) The 96 trinucleotide mutational spectra of trunk (right) and non-trunk (left) 
mutations.   (B) Proportion of 4 distinct mutation types is shown for trunk and non-
trunk mutations.   (C) Dot plots showing the distribution of mutation signature to 
each patient in trunk and non-trunk(left) and pie charts indicating signature 
distributions (right). 
 
Figure 4: Heterogeneity of CNV and chromosomal instability.  (A) Heatmap of 
copy number variants. X-axis shows chromosomal coordinates. The right band 
displays the ploidy status.  (B) The significance of focal somatic CNAs in 99 ICCs. 
GISTIC q-values (x-axis) for deletions (right, blue) and amplifications (left, red) are 
plotted across the genome (y-axis). Known or putative gene targets within the peak 
regions are indicated.  (C) The correlation of the ploidy and wGII. Positive 
correlation between the ploidy and wGII is observed and all regions have evidence of 
CIN.   
 
Figure 5: Polyclonal seeding and adaptive therapy   (A) A timeline of clinical 
history in ICC1239P and ICC1239R. Representative CT/MRI images of each tumor 
are shown below and the red circles indicate the locations of tumors.   (B) The brief 
diagram of phylogenetic tree. The orange branch and grey branch represent the 
ICC1239R and ICC1239P, respectively.   (C) CCF comparisons for the primary and 
recurrent regions. In the plot, the CCF of all SNVs for all primary sites (y-axis) is 
plotted against the 3 recurrent sites (x-axis).   (D) The viable test of cisplatin 
treatment of PDPCs from R1/R2. P=0.008.    (E) Fitness landscape with and 
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without chemotherapy[left] and a model based on adaptive therapy which may be 
suitable for ICC1239R to prolong patient survival time[right]. 
 
 
Figure 6: A model of the evolutionary history of ICC.   ICC evolves through 
acquisition of driver genes. Lots of mechanisms are involved in branch diversity, 
which is collectively shaped by positive selection, parallel evolution and chromosome 
instability. GD: genome doubling; LOH loss of heterogeneity. 
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Highlights 
 Branch evolution is the predominant pattern in ICC, which is collectively 
shaped by parallel evolution and chromosome instability. 
 ICC may metastasize through polyclonal seeding and the competition between 
subclonal population can be used to develop new treatment strategy, like 
adaptive therapy. 
 Targeted therapy against truncal alterations, such as IDH1, JAK1, and KRAS 
mutations and EGFR amplification, can be a promising treatment strategy for 
ICC patients. 
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